{"id":794195,"date":"2026-03-06T10:23:01","date_gmt":"2026-03-06T10:23:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=794195"},"modified":"2026-03-06T10:23:01","modified_gmt":"2026-03-06T10:23:01","slug":"csl-behring-hemgenix-market-size-expansion-of-several-folds-by-2034","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/csl-behring-hemgenix-market-size-expansion-of-several-folds-by-2034_794195.html","title":{"rendered":"CSL Behring &#8220;HEMGENIX&#8221; Market size expansion of Several Folds by 2034"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1772739493.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CSL Behring &quot;HEMGENIX&quot; Market size expansion of Several Folds by 2034\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1772739493.jpg\" alt=\"CSL Behring &quot;HEMGENIX&quot; Market size expansion of Several Folds by 2034\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on HEMGENIX (CSL Behring)  providing insights into the drug market landscape and market forecast of HEMGENIX upto 2034.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on HEMGENIX (CSL Behring) providing insights into the drug market landscape and market forecast of HEMGENIX upto 2034. The report, titled &#8220;HEMGENIX Sales Forecast, and Market Size Analysis &ndash; 2034&#8221; is now available for review and analysis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Are you interested in finding out the projected market size of HEMGENIX in 2034? HEMGENIX Market Forecast<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemgenix-sales-forecast-and-market-size-analysis?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/hemgenix-sales-forecast-and-market-size-analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving HEMGENIX Growth<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>1. Market Share Gains and New Patient Starts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>HEMGENIX continues to advance adoption as the first and only FDA- and EMA-authorized gene therapy for adults with severe and moderately severe hemophilia B, offering a potential one-time durable treatment compared with chronic factor replacement or prophylactic therapies.<\/p>\n<\/li>\n<li>\n<p>New patient starts are increasing as treatment centers in Europe and North America begin administering HEMGENIX in real-world settings following regulatory approvals and reimbursement negotiations.<\/p>\n<\/li>\n<li>\n<p>Early commercial use in markets like Germany and France shows growing clinician confidence and patient interest, especially for eligible patients seeking reduced treatment burden.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>2. Expansion Across Key Indications<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Severe and Moderately Severe Hemophilia B: HEMGENIX is indicated for adults with congenital Factor IX deficiency who currently use Factor IX prophylaxis or have experienced repeated serious bleeding episodes.<\/p>\n<\/li>\n<li>\n<p>The therapy delivers a functional gene enabling patients&rsquo; liver cells to produce Factor IX, reducing the risk of bleeding and potentially eliminating the need for routine infusions.<\/p>\n<\/li>\n<li>\n<p>Unlike traditional factor replacement therapies administered regularly, HEMGENIX&rsquo;s one-time infusion creates a durable treatment effect, which is particularly compelling for patients aiming to minimize treatment burden.<\/p>\n<\/li>\n<li>\n<p>No additional indications beyond hemophilia B have been approved yet, though long-term gene therapy research and real-world evidence could support broader applications within rare bleeding disorders.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The HEMGENIX Market Report offers projected sales forecasts for HEMGENIX for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.<\/p>\n<p style=\"text-align: justify;\"><strong>CSL Behring&rsquo;s HEMGENIX<\/strong> is serving as a beacon of hope for the patients suffering from the hemophilia B.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>What is a HEMGENIX Prescribed for?<\/strong><\/p>\n<p style=\"text-align: justify;\">Hemgenix is prescribed to treat Hemophilia B in adults. It is a one-time gene therapy designed for patients with moderate to severe hemophilia B who require ongoing Factor IX replacement therapy or experience frequent bleeding episodes.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=csl-behring-hemgenix-market-size-expansion-of-several-folds-by-2034\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=csl-behring-hemgenix-market-size-expansion-of-several-folds-by-2034\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on HEMGENIX (CSL Behring) providing insights into the drug market landscape and market forecast of HEMGENIX upto 2034. &nbsp; [Las Vegas, United States] DelveInsight, a leader in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/csl-behring-hemgenix-market-size-expansion-of-several-folds-by-2034_794195.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,423],"tags":[],"class_list":["post-794195","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/794195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=794195"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/794195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=794195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=794195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=794195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}